Synonyms: 9-hydroxyrisperidone | Invega® | Ro-76477 | Ro-92670
paliperidone is an approved drug (FDA (2006), EMA (2007))
Compound class:
Synthetic organic
Comment: Paliperidone is an atypical antipsychotic. Mechanistically it is a dopamine receptor and 5-HT2A receptor antagonist.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: paliperidone |
|
No information available. |
Summary of Clinical Use |
Used to treat psychotic or manic symptoms of schizophrenia. In November 2014, the US FDA granted a supplemental New Drug Application (sNDA) for paliperidone palmitate (PubChem CID 9852746) as a treatment for schizoaffective disorder as either monotherapy or adjunctive therapy. This sNDA will be scrutinised under priority review, a mechanism whereby drugs may be approved more quickly, if they are found to offer significant improvement in the treatment of serious conditions, over currently available therapies. Following publication of results from a Phase 3 clinical trial [1], the FDA formally approved the use of paliperidone palmitate (trade named Invega Trinza) as a long-acting schizophrenia medication in May 2015. Invega Trinza has a dosing interval of three months. |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |